Google backed company, 23andMe, has already partially sequenced over 1.2 million genomes, making the genetic testing company an attractive prospect for academic researchers as well as pharmaceutical companies such as Genentech and Pfizer. The new study is a collaboration between scientists from Harvard Medical School (HMS) and Broad Institute of MIT and Harvard, which was founded by geneticist Jennifer Doudna in 2009.
Google backed company, 23andMe, has already partially sequenced over 1.2 million genomes, making the genetic testing company an attractive prospect for academic researchers as well as pharmaceutical companies such as Genentech and Pfizer. With the company looking to monetise its genetic data, patient advocates have suggested that profits be shared with its customers.